alog_pcfb {MBNMAtime}R Documentation

Studies of alogliptin for lowering blood glucose concentration in patients with type II diabetes

Description

A dataset from a systematic review of Randomised-Controlled Trials (RCTs) comparing different doses of alogliptin with placebo (Langford et al. 2016). The systematic review was simply performed and was intended to provide data to illustrate a statistical methodology rather than for clinical inference. Alogliptin is a treatment aimed at reducing blood glucose concentration in type II diabetes. The outcome is continuous, and aggregate data responses correspond to the mean change in HbA1c from baseline to follow-up. The dataset includes 14 Randomised-Controlled Trials (RCTs), comparing 5 different doses of alogliptin with placebo, leading to 6 different treatments (combination of dose and agent) within the network.

Usage

alog_pcfb

Format

A data frame in long format (one row per arm and study), with 46 rows and 9 variables:

Details

alog_pcfb is a data frame in long format (one row per observation, arm and study), with the variables studyID, clinicaltrialGov_ID, agent, dose, treatment, time, y, se, and n.

References

Langford O, Aronson JK, van Valkenhoef G, Stevens RJ (2016). “Methods for meta-analysis of pharmacodynamic dose-response data with application to multi-arm studies of alogliptin.” Stat Methods Med Res. ISSN 1477-0334 (Electronic) 0962-2802 (Linking), doi:10.1177/0962280216637093, https://pubmed.ncbi.nlm.nih.gov/26994216/.


[Package MBNMAtime version 0.2.4 Index]